Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Recce Pharmaceuticals stock price, quote, forecast and news

RCE.AX
AU000000RCE5
A2ADQM

Price

0.52 AUD
Today +/-
+0 AUD
Today %
+0 %
P

Recce Pharmaceuticals stock price

AUD
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Recce Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Recce Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Recce Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Recce Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Recce Pharmaceuticals Stock Price History

DateRecce Pharmaceuticals Price
9/18/20240.52 AUD
9/17/20240.52 AUD
9/16/20240.52 AUD
9/13/20240.51 AUD
9/12/20240.52 AUD
9/11/20240.52 AUD
9/10/20240.52 AUD
9/9/20240.54 AUD
9/6/20240.54 AUD
9/5/20240.51 AUD
9/4/20240.50 AUD
9/3/20240.49 AUD
9/2/20240.48 AUD
8/30/20240.49 AUD
8/29/20240.50 AUD
8/28/20240.50 AUD
8/27/20240.51 AUD
8/26/20240.51 AUD
8/23/20240.49 AUD
8/22/20240.48 AUD
8/21/20240.48 AUD

Recce Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Recce Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Recce Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Recce Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Recce Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Recce Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Recce Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Recce Pharmaceuticals’s growth potential.

Recce Pharmaceuticals Revenue, EBIT and net profit per share

DateRecce Pharmaceuticals RevenueRecce Pharmaceuticals EBITRecce Pharmaceuticals Net Income
2026e6.56 M AUD-68.91 M AUD-79.53 M AUD
2025e9.71 M AUD-13.22 M AUD-16.37 M AUD
20245.24 M AUD-16.81 M AUD-17.66 M AUD
20234.43 M AUD-12.81 M AUD-13.08 M AUD
20223.18 M AUD-10.97 M AUD-10.99 M AUD
20211.96 M AUD-13.5 M AUD-13.51 M AUD
20201.15 M AUD-4.26 M AUD-4.32 M AUD
2019686,620 AUD-2.73 M AUD-2.79 M AUD
20181.3 M AUD-1.62 M AUD-1.67 M AUD
2017189,920 AUD-2.99 M AUD-3.03 M AUD
2016177,020 AUD-4.64 M AUD-4.84 M AUD
2015113,850 AUD-449,920 AUD-450,170 AUD
2014100,000 AUD-270,000 AUD-270,000 AUD
20130 AUD-290,000 AUD-290,000 AUD
20120 AUD-20,000 AUD-20,000 AUD

Recce Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M AUD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M AUD)EBIT (M AUD)EBIT MARGIN (%)NET INCOME (M AUD)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20122013201420152016201720182019202020212022202320242025e2026e
000000101134596
----------200.0033.3325.0080.00-33.33
---------------
000000000000000
0000-4-2-1-2-4-13-10-12-16-13-68
-------100.00--400.00-1,300.00-333.33-300.00-320.00-144.44-1,133.33
0000-4-3-1-2-4-13-10-13-17-16-79
------25.00-66.67100.00100.00225.00-23.0830.0030.77-5.88393.75
67.4467.4467.4433.3156.2276.6184.7294.47127.21156.96175.85175.72177.100
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Recce Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Recce Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M AUD)RECEIVABLES (k AUD)OTHER REC. (k AUD)INVENTORIES (M AUD)OTHER CURRENT LIAB. (k AUD)CURRENT ASSETS (M AUD)TANGIBLE ASSETS (M AUD)LONG-T. INVEST. (M AUD)LONG-T. REC. (M AUD)INTANGIBLE ASSETS (k AUD)GOODWILL (M AUD)OTHER NON-CURRENT ASSETS (M AUD)NON-CURRENT ASSETS (M AUD)TOTAL ASSETS (M AUD)LIABILITIESCOMMON STOCK (M AUD)ADDITIONAL PAID-IN CAPITAL (M AUD)RETAINED EARNINGS (M AUD)OTHER EQUITY (M AUD)UNREAL. GAINS/LOSSES (M AUD)EQUITY (M AUD)LIABILITIES (M AUD)PROVISIONS (k AUD)OTHER SHORT-TERM LIAB. (M AUD)SHORT-TERM DEBTS (k AUD)LONG-TERM DEBT PORTION (k AUD)SHORT-TERM REC. (M AUD)LONG-T. LIAB. (k AUD)DEFERRED TAXES (M AUD)OTHER LIAB. (k AUD)LONG-T. LIABILITIES (k AUD)DEBT (M AUD)TOTAL CAPITAL (M AUD)
2012201320142015201620172018201920202021202220232024
                         
00.04003.591.090.680.42.6820.8711.61.614.46
000.010060.1920.9636.5241.36245.48182.4790.67159.43
000000000000291.09
0000000000000
00006.433.377.8213.215.8562.4400.93248.22221.67
00.04003.61.150.710.452.7421.1812.191.955.14
0.030.04000.080.310.440.470.50.50.440.611.23
0000000000000
0000000000000
0001.190.7100000000
0000000000000
0000000000000
0.030.04000.080.310.440.470.50.50.440.611.23
0.030.08003.681.461.140.923.2421.6812.622.566.37
                         
0.330.51007.428.2410.0311.5718.4743.343.9744.1154.84
0000000000000
-0.3-0.5900-3.91-7.64-9.34-11.98-16.15-22.79-33.91-46.7-64.36
0000000000000
0000000000000
0.03-0.08003.510.590.69-0.412.3120.510.06-2.59-9.52
00.15000.020.530.230.120.160.580.581.164.59
00026.7692.20052.6101.9452.58173.28111.15118.57
00000.080.160.180.360.540.341.623.4310.14
00006.9802.86737.4100000
0000000083.24112.5974.76147.88224.09
00.1500.030.20.690.421.270.891.082.454.8515.07
00000161.2900014.360102.69587.11
0000000000000
000011.7422.8632.4354.4546.385.22115.31192.13236.55
000011.74184.1532.4354.4546.399.58115.31294.82823.66
00.1500.030.210.870.451.330.931.182.565.1415.89
0.030.0700.033.721.461.140.923.2421.6812.622.566.37
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Recce Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Recce Pharmaceuticals's financial health and stability.

Assets

Recce Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Recce Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Recce Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Recce Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M AUD)DEPRECIATION (M AUD)DEFERRED TAXES (M AUD)CHANGES IN WORKING CAPITAL (M AUD)NON-CASH ITEM (M AUD)PAID INTEREST (M AUD)PAID TAXES (M AUD)NET CASH FLOW FROM OPERATING ACTIVITIES (M AUD)CAPITAL EXPENDITURES (M AUD)CASH FLOW FROM INVESTING ACTIVITIES (M AUD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M AUD)INTEREST INCOME AND EXPENSES (M AUD)NET DEBT CHANGE (M AUD)NET CHANGE IN EQUITY (M AUD)CASH FLOW FROM FINANCING ACTIVITIES (M AUD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (AUD)TOTAL DIVIDENDS PAID (M AUD)NET CHANGE IN CASH FLOW (M AUD)FREE CASH FLOW (M AUD)SHARE-BASED COMPENSATION (M AUD)
20152016201720182019202020212022
00000000
00000000
00000000
00000000
00000000
00000000
00000000
0-1-2-1-2-3-7-9
00000000
00000000
00000000
00000000
00000000
040116280
040126260
-------1.00-
00000000
01-5-2-2-110-18
-0.33-1.69-2.74-1.91-2.7-3.81-7.93-9.05
00000000

Recce Pharmaceuticals stock margins

The Recce Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Recce Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Recce Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Recce Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Recce Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Recce Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Recce Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Recce Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Recce Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Recce Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Recce Pharmaceuticals Margin History

Recce Pharmaceuticals Gross marginRecce Pharmaceuticals Profit marginRecce Pharmaceuticals EBIT marginRecce Pharmaceuticals Profit margin
2026e0 %-1,050.83 %-1,212.79 %
2025e0 %-136.15 %-168.64 %
20240 %-321.12 %-337.29 %
20230 %-289.1 %-295.11 %
20220 %-345.55 %-345.92 %
20210 %-687.7 %-688.32 %
20200 %-371.26 %-376.18 %
20190 %-397.97 %-406.22 %
20180 %-124.56 %-128.74 %
20170 %-1,576.81 %-1,593.04 %
20160 %-2,623.61 %-2,734.36 %
20150 %-395.19 %-395.41 %
20140 %-270 %-270 %
20130 %0 %0 %
20120 %0 %0 %

Recce Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Recce Pharmaceuticals earnings per share therefore indicates how much revenue Recce Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Recce Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Recce Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Recce Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Recce Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Recce Pharmaceuticals Revenue, EBIT and net profit per share

DateRecce Pharmaceuticals Sales per ShareRecce Pharmaceuticals EBIT per shareRecce Pharmaceuticals Earnings per Share
2026e0.03 AUD0 AUD-0.34 AUD
2025e0.04 AUD0 AUD-0.07 AUD
20240.03 AUD-0.09 AUD-0.1 AUD
20230.03 AUD-0.07 AUD-0.07 AUD
20220.02 AUD-0.06 AUD-0.06 AUD
20210.01 AUD-0.09 AUD-0.09 AUD
20200.01 AUD-0.03 AUD-0.03 AUD
20190.01 AUD-0.03 AUD-0.03 AUD
20180.02 AUD-0.02 AUD-0.02 AUD
20170 AUD-0.04 AUD-0.04 AUD
20160 AUD-0.08 AUD-0.09 AUD
20150 AUD-0.01 AUD-0.01 AUD
20140 AUD-0 AUD-0 AUD
20130 AUD-0 AUD-0 AUD
20120 AUD-0 AUD-0 AUD

Recce Pharmaceuticals business model

Recce Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Recce Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Recce Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Recce Pharmaceuticals shares outstanding

The number of shares was Recce Pharmaceuticals in 2023 — This indicates how many shares 175.718 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Recce Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Recce Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Recce Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Recce Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Recce Pharmaceuticals.

Recce Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
6.53881 % FIL Investment Management (Hong Kong) Limited15,144,4669,706,5729/18/2023
3.02234 % Rogers (M)7,000,0002,000,0009/18/2023
2.92103 % Graham (James Hamilton Bray)6,765,362233,4309/29/2023
15.98742 % Melrose (Graham John Hamilton Ph.D.)37,028,31109/18/2023
1.94293 % Acuity Capital Investment Management Pty. Ltd.4,500,00009/18/2023
1.37500 % Acewood Investment Pty. Ltd.3,184,61609/18/2023
1.25643 % Liddelow (John James)2,910,000860,0009/18/2023
1.16881 % Dilizia (Michele Keryn)2,707,080-836,40512/7/2023
1.07941 % Pejay Pty. Ltd.2,500,000250,0009/18/2023
0.92565 % Ldu Pty. Ltd.2,143,881-1,374,2999/18/2023
1
2
3

Recce Pharmaceuticals Executives and Management Board

Mr. James Graham
Recce Pharmaceuticals Chief Executive Officer, Managing Director, Executive Director (since 2015)
Compensation 548,202 AUD
Ms. Michele Dilizia
Recce Pharmaceuticals Chief Scientific Officer, Executive Director (since 2015)
Compensation 368,942 AUD
Dr. Justin Ward
Recce Pharmaceuticals Executive Director and Principal Quality Chemist (since 2019)
Compensation 207,971 AUD
Dr. John Prendergast
Recce Pharmaceuticals Independent Non- Executive Chairman of the Board
Compensation 120,000 AUD
Dr. Alan Dunton68
Recce Pharmaceuticals Non-Executive Independent Director
Compensation 60,000 AUD
1
2

Most common questions regarding Recce Pharmaceuticals

What is the P/E ratio of Recce Pharmaceuticals 2024?

The Recce Pharmaceuticals P/E ratio is -5.16.

What is the P/S ratio of Recce Pharmaceuticals 2024?

The Recce Pharmaceuticals P/S ratio is 17.42.

What is the AlleAktien quality score of Recce Pharmaceuticals?

The AlleAktien quality score for Recce Pharmaceuticals is 9/10.

What is the revenue of Recce Pharmaceuticals 2024?

The Recce Pharmaceuticals revenue is 5.24 M AUD.

How high is the profit of Recce Pharmaceuticals 2024?

The Recce Pharmaceuticals profit is -17.66 M AUD.

What is the business model of Recce Pharmaceuticals

No history available for Recce Pharmaceuticals.

What is the Recce Pharmaceuticals dividend?

Recce Pharmaceuticals pays a dividend of 0 AUD distributed over payouts per year.

How often does Recce Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Recce Pharmaceuticals or the company does not pay out a dividend.

What is the Recce Pharmaceuticals ISIN?

The ISIN of Recce Pharmaceuticals is AU000000RCE5.

What is the Recce Pharmaceuticals WKN?

The WKN of Recce Pharmaceuticals is A2ADQM.

What is the Recce Pharmaceuticals ticker?

The ticker of Recce Pharmaceuticals is RCE.AX.

How much dividend does Recce Pharmaceuticals pay?

Over the past 12 months, Recce Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Recce Pharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Recce Pharmaceuticals?

The current dividend yield of Recce Pharmaceuticals is .

When does Recce Pharmaceuticals pay dividends?

Recce Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Recce Pharmaceuticals?

Recce Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Recce Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Recce Pharmaceuticals located?

Recce Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Recce Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Recce Pharmaceuticals from 9/19/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Recce Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Recce Pharmaceuticals in the year 2023?

In the year 2023, Recce Pharmaceuticals distributed 0 AUD as dividends.

In which currency does Recce Pharmaceuticals pay out the dividend?

The dividends of Recce Pharmaceuticals are distributed in AUD.

All fundamentals about Recce Pharmaceuticals

Our stock analysis for Recce Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Recce Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.